BIODLINK-B (01875) rose more than 11% again, with its share price having doubled since the start of the year. At the time of writing, the stock was up 9.94% to HK$5.75, with a turnover of HK$21.0874 million. The surge follows an announcement from WUXI XDC that its cash offer to acquire BIODLINK has received valid acceptance for 60% of the company's equity, making the share offer officially effective. Through this controlling stake acquisition, WUXI XDC will further enrich its project portfolio, expand its customer base, enhance production capacity allocation, and continue to solidify its leading position in the global ADC CRDMO field. According to documents disclosed by the Hong Kong Stock Exchange, on March 17, WuXi XDC Cayman Inc. acquired 464 million ordinary shares of BIODLINK off-market at an average price of HK$4.0 per share, valued at approximately HK$1.855 billion. Following this acquisition, its latest shareholding stands at 464 million shares, with its long position increasing from 0.00% to 60.00%.